Citi Reiterates Buy Rating on Abbott Labs (ABT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Goldman Sachs Upgrades NIO (NIO) to Buy
- IBM misses Q2 targets as mainframe and software sales disappoint
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Abbott Labs (ABT) PT Raised to $135 at JPMorgan
October 10, 2024 5:42 AM EDTJPMorgan analyst Robbie Marcus raised the price target on Abbott Labs (NYSE: ABT) to $135.00 (from $125.00) while maintaining a Overweight rating.
The analyst comments "Abbott is set to report 3Q24 results before the open on Wednesday, October 16. With volumes healthy, Fx modestly better, and price still a tailwind, we see... More
Oppenheimer Starts Abbott Labs (ABT) at Outperform
October 8, 2024 6:02 AM EDTOppenheimer analyst Suraj Kalia initiates coverage on Abbott Labs (NYSE: ABT) with a Outperform rating and a price target of $130.00.
The analyst comments "We are initiating coverage of Abbott Labs, a large-cap diversified healthcare play, with an OP... More
